GlassScriptPhysician profile
Jon R Campitelli
NPI 1245647551
$2,081.03
in general payments reported to CMS, 2019-2025
27 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $275 · 2021: $248 · 2022: $362 · 2023: $304 · 2024: $45.30 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.35 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.40 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $229.85 | 2019-2025 | |
| Exact Sciences Corporation | $138.41 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kvk-Tech, INC. | $132.87 | 2019 | |
| Glaxosmithkline, LLC. | $130.35 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $120.10 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $105.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $100.16 | 2021-2025 | |
| Intuitive Surgical, INC. | $97.37 | 2019 | |
| Amarin Pharma, INC. | $91.64 | 2020-2021 | |
| Amgen INC. | $64.16 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.79 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $57.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.15 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $52.83 | 2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $30.20 | 2020-2023 | Wellbutrin, Aplenzin |
| Eisai INC. | $27.00 | 2020 | |
| Alnylam Pharmaceuticals INC. | $26.34 | 2022 | |
| Esperion Therapeutics, INC. | $23.19 | 2020-2021 | |
| Sanofi Pasteur INC. | $22.79 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.78 | 2020 | |
| Hologic Sales and Service, LLC | $15.73 | 2020 | |
| Gilead Sciences, INC. | $15.42 | 2019 | |
| Merck Sharp & Dohme LLC | $13.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Campitelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.